GAITHERSBURG, MD., November 12 /CNW/ - Beginning December 1, 2007, Bridge
Pharmaceuticals, Inc. (Bridge) will offer a new service for obtaining
occupational safety studies on compound exposure during chemical manufacture
and handling. With faster study turnarounds and flexible data reporting,
Bridge will make it easier for companies to guard their employees against
chemical exposure hazards.
Before a new compound can be manufactured, regulators require toxicology
studies to judge the risks of acute exposure (i.e., exposure lasting a few
minutes to a few days) to the new compound. Testing guidelines are set by the
U.S. Federal Hazardous Substances Act (FHSA), Department of Transportation,
and Environmental Protection Agency, the European Union's Organization for
Economic Co-Operation and Development (OECD), and the Ministry of Agriculture,
Forestries, and Fisheries (MAFF) in Japan. Because of the complexity of these
tests and their guidelines, occupational safety chemical exposure studies
often take four weeks.
At Bridge's U.S. facility in Gaithersburg, studies performed as non-GLP
or fully GLP compliant will have turnarounds no longer than three weeks.
Chemical, pharmaceutical, and biotech companies need occupational safety
studies for thousands of compounds each year. With so many compounds to
evaluate, placing studies with Bridge for whole series of compounds will mean
major timesavings without compromising safety.
Bridge will further distinguish itself from competitors by offering
customized reporting templates that format data however customers find most
convenient. As a result, test results will be easier to interpret. By
combining faster studies with more convenient reporting formats, Bridge's new
Occupational Safety Program will help companies minimize compound-related
occupational safety hazards more quickly and easily.
Bridge's Occupational Safety Testing Program will be open to customers
worldwide. Following inauguration of the program in Gaithersburg, Bridge will
offer the same services in its China facility in Beijing beginning in early
Bridge is one of the first preclinical contract research organization
(CRO) to provide US-level drug development services in both the US and Asia.
Bridge is headquartered in the United States with laboratories in
Gaithersburg, Maryland and Beijing, China. Bridge focuses on providing
cost-effective, FDA compliant drug development services for pharmaceutical,
biotech and government clients. Bridge's current capabilities in preclinical
drug development include GLP compliant toxicology, safety pharmacology,
pathology and bioanalytical services. For more information, visit
http://www.bridgecro.com or contact email@example.com.
For further information:
For further information: Bridge Pharmaceuticals, Inc. Marisa Pawlewicz,